A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

LY007 - China Biotech Services

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

https://meetings.asco.org/abstracts-presentations/238977/

Zixun Yan; Lingshuang Sheng; Li Wang; Wen Wu; Yilun Zhang; Rong Shen; Weiguo Cao; Lei Li; Sheng Chen; Xufeng Jiang; Hongmei Yi; Qi Song; Shu Cheng; Peng-Peng Xu; Jianyong Li; Weili Zhao

Apr 25, 2024